Kyle E Giesler1, Dennis C Liotta1. 1. Department of Chemistry, Emory University , 1521 Dickey Drive NE, Emerson 305, Atlanta, Georgia 30322, United States.
Abstract
The pharmacokinetic properties of tenofovir (TFV) and other charged nucleoside analogues are dramatically improved upon conjugation to a lipid prodrug. We previously prepared reduction-sensitive lipid conjugates of TFV that demonstrate superior antiviral activity compared to other lipid conjugates including the clinically approved formulation, tenofovir disoproxil fumarate (TDF). In continuation of that work, we have synthesized next-generation conjugates with reduced cytotoxicity that retain potent antiviral activity against HIV-1 and HBV with a therapeutic index >100000 for our most potent conjugate. We also show that disulfide reduction is not responsible for prodrug cleavage unless 3-exo-tet intramolecular cyclization can occur, suggesting that enzymatic hydrolysis is predominantly responsible for activity of our prodrugs in vitro.
The pharmacokinetic properties of tenofovir (n class="Chemical">TFV) and other charged nucleoside analogues are dramatically improved upon conjugation to a lipid prodrug. We previously prepared reduction-sensitive lipid conjugates of TFV that demonstrate superior antiviral activity compared to other lipid conjugates including the clinically approved formulation, tenofovir disoproxil fumarate (TDF). In continuation of that work, we have synthesized next-generation conjugates with reduced cytotoxicity that retain potent antiviral activity against HIV-1 and HBV with a therapeutic index >100000 for our most potent conjugate. We also show that disulfide reduction is not responsible for prodrug cleavage unless 3-exo-tet intramolecular cyclization can occur, suggesting that enzymatic hydrolysis is predominantly responsible for activity of our prodrugs in vitro.
Authors: Martin Markowitz; Andrew Zolopa; Kathleen Squires; Peter Ruane; Dion Coakley; Brian Kearney; Lijie Zhong; Michael Wulfsohn; Michael D Miller; William A Lee Journal: J Antimicrob Chemother Date: 2014-02-06 Impact factor: 5.790
Authors: W Li; P A Escarpe; E J Eisenberg; K C Cundy; C Sweet; K J Jakeman; J Merson; W Lew; M Williams; L Zhang; C U Kim; N Bischofberger; M S Chen; D B Mendel Journal: Antimicrob Agents Chemother Date: 1998-03 Impact factor: 5.191
Authors: George R Painter; Merrick R Almond; Lawrence C Trost; Bernhard M Lampert; Johan Neyts; Erik De Clercq; Brent E Korba; Kathy A Aldern; James R Beadle; Karl Y Hostetler Journal: Antimicrob Agents Chemother Date: 2007-07-23 Impact factor: 5.191
Authors: Pamela Hummert; Teresa L Parsons; Laura M Ensign; Thuy Hoang; Mark A Marzinke Journal: J Pharm Biomed Anal Date: 2018-02-08 Impact factor: 3.935